Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies
October 01 2024 - 5:45AM
Business Wire
Latest preclinical studies reveal significant
improvements in stability, efficacy, and KRAS targeting range for
next-generation siRNA candidate SIL-204
Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the
“Company”), a clinical-stage biotech developing RNA interference
(RNAi) therapies for KRAS-driven cancers, today announced new
preclinical findings for SIL-204, its second-generation siRNA
candidate, following the optimization of its extended-release
formulation. These latest findings demonstrate that the latest
SIL-204-microparticle formulation can inhibit the growth and induce
necrosis of the human pancreatic cell line that bears the KRAS G12D
mutation xenotransplanted into mice. Given that this mutation
constitutes the largest segment of pancreatic cancer subtypes, it
represents a significant in the development of SIL-204.
Key new pre-clinical findings include:
- Significant Anti-tumor Activity: In recent mouse
xenograft studies, SIL-204 demonstrated substantial tumor reduction
in the human pancreatic tumor cell lines with the KRAS G12D (Panc
-1) mutations using the innovative approach of oncogene silencing
with siRNA. Previous studies showed this effect using unformulated
siRNA with daily injections. The new studies further show this
effect with a single administration of SIL-204 encapsulated in an
extended-release formulation. Moreover, histopathological
examination of treated tumors showed a very high induction of tumor
necrosis.
- Improved Formulation In Vivo: The transition from PLGA
depot rods to PLGA microparticles (MPs) has resulted in a superior
extended-release profile, enhancing the therapeutic potential. We
now report in vivo results indicating that our new modified
PLGA-microparticle formulation has superior properties over
previous extended-release formulations (Loder).
Silexion plans to initiate toxicology studies with SIL-204
within the upcoming months and has plans to advance SIL-204 into
Phase 2/3 clinical trials in the first half of 2026, focusing
initially on locally advanced pancreatic cancer (LAPC) which has a
notoriously high mortality rate. In parallel, the company plans to
initiate preclinical studies for SIL-204, in colorectal cancer
models.
"These optimizations represent a significant step forward in our
development of SIL-204," said Ilan Hadar, Chairman and CEO of
Silexion. "The improvements in cellular uptake and the enhanced
extended-release formulation further strengthen our confidence in
SIL-204's potential. We look forward to commencing our next set of
studies in preparation for our Phase 2/3 clinical trial."
About Silexion Therapeutics
Silexion Therapeutics (NASDAQ: SLXN) is a pioneering
clinical-stage, oncology-focused biotechnology company developing
innovative RNA interference (RNAi) therapies to treat solid tumors
driven by KRAS mutations, the most common oncogenic driver in human
cancers. The company's first-generation product, LODER™, has shown
promising results in a Phase 2 trial for non-resectable pancreatic
cancer. Silexion is also advancing its next-generation siRNA
candidate, SIL-204, designed to target a broader range of KRAS
mutations and showing significant potential in preclinical studies.
The company remains committed to pushing the boundaries of
therapeutic innovation in oncology, with a focus on improving
outcomes for patients with difficult-to-treat cancers. For more
information please visit: https://silexion.com
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the federal securities laws. All statements other
than statements of historical fact contained in this communication,
including statements regarding Silexion’s business strategy and
plans and objectives of management for future operations, are
forward-looking statements. These forward-looking statements are
generally identified by terminology such as "pro forma", "may",
"should", "could", "might", "plan", "possible", "project",
"strive", "budget", "forecast", "expect", "intend", "will",
"estimate", "anticipate", "believe", "predict", "potential" or
"continue", or the negatives of these terms or variations of them
or similar terminology. Forward-looking statements involve a number
of risks, uncertainties, and assumptions, and actual results or
events may differ materially from those projected or implied in
those statements. Important factors that could cause such
differences include, but are not limited to: (i) Silexion’s market
opportunity; (ii) Silexion’s strategy, future operations, financial
position, projected costs, prospects and plans; (iii) the impact of
the regulatory environment and complexities with compliance related
to such environment; (iv) expectations regarding future
partnerships or other relationships with third parties; (v)
Silexion’s future capital requirements and sources and uses of
cash, including Silexion’s ability to obtain additional capital in
the future; and (vi) other risks and uncertainties set forth in the
documents filed or to be filed with the SEC by the company,
including the proxy statement/prospectus filed with the SEC on July
17, 2024. Silexion cautions you against placing undue reliance on
forward-looking statements, which reflect current beliefs and are
based on information currently available as of the date a
forward-looking statement is made. Forward-looking statements set
forth herein speak only as of the date they are made. Silexion
undertakes no obligation to revise forward-looking statements to
reflect future events, changes in circumstances, or changes in
beliefs, except as otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241001946039/en/
Company Contact Silexion Therapeutics Corp Ms. Mirit
Horenshtein Hadar, CFO mirit@silexion.com
Investor Contact ARX | Capital Markets Advisors North
American Equities Desk silexion@arxadvisory.com
Silexion Therapeutics (NASDAQ:SLXN)
Historical Stock Chart
From Oct 2024 to Nov 2024
Silexion Therapeutics (NASDAQ:SLXN)
Historical Stock Chart
From Nov 2023 to Nov 2024